Semaglutide specifically showed an average weight loss of 9.2 percent in patients with overweight and obesity over 68 weeks in SUSTAIN 12
Before taking Pepto-Bismol with Wegovy, you should: Consult your GP or prescribing clinician, particularly if symptoms are severe or persistent Check for contraindications to bismuth subsalicylate (such as aspirin/salicylate allergy, bleeding disorders, kidney problems, pregnancy, breastfeeding, or if under 16 years of age) Consider whether your symptoms might be better managed through Wegovy dose adjustment Avoid prolonged use of Pepto-Bismol without medical advice Be aware that bismuth can cause harmless darkening of stools and tongue, which should not be confused with bleeding If gastrointestinal symptoms are significantly impacting your quality of life, contact your healthcare provider rather than relying solely on over-the-counter remedies

Prior to regulatory approval, the SCALE, phase III trials demonstrated a sustained 2-year weight loss with liraglutide treatment as an adjunct to diet and exercise in non-diabetic participants (140, 141), strengthening the argument that effects are largely independent of glycaemic modulation
These habits work synergistically with the medication, enhancing its effects and helping you achieve lasting results
This is an example of habit stacking